NaCo·AI is MediSense's computational drug discovery engine — transforming clinically validated natural product scaffolds into patentable new chemical entities for human orphan diseases and companion animal health.
Most drug discovery starts from blank chemistry. We don't. Our starting compounds come from pharmacopoeias with decades to centuries of documented clinical use — with published pharmacokinetic data, known safety profiles, and real biological signals.
The platform models how each molecule binds at residue-level resolution, then uses that structural feedback to guide molecular modifications — fluoroalkyl metabolic armor, aromatic ether binding enhancement, and systematic ADMET optimization. It doesn't just screen. It designs.
Every computational prediction is held accountable to wet-lab reality. Lead compounds are synthesized and validated through binding assays with global CROs. Each round of experimental data improves predictions across the entire compound matrix.
We operate a dual-track strategy: orphan disease assets targeting Priority Review Voucher (PRV) and Orphan Drug Designation (ODD) pathways, alongside companion animal licensing for near-term revenue. Both tracks run on the same NaCo·AI computational foundation.
MediSense also develops SilenEar, an adaptive neuromodulation platform for tinnitus. Learn more at silenear.com.
MediSense Inc.
Taichung, Taiwan